Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial.

In 968 people with stage III colon cancer, ctDNA-guided de-escalation did not meet non-inferiority and escalation did not improve recurrence-free survival, although ctDNA-negative disease had a much lower recurrence risk.

Nature MedicinePubMed 41115959DOI 10.1038/s41591-025-04030-w